Published in Arthritis Res Ther on June 29, 2011
YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol (2013) 0.99
Chitin-binding domains of Escherichia coli ChiA mediate interactions with intestinal epithelial cells in mice with colitis. Gastroenterology (2013) 0.91
The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS One (2012) 0.84
Correlation of chitinase 3-like 1 single nucleotide polymorphisms and haplotypes with uterine cervical cancer in Taiwanese women. PLoS One (2014) 0.76
Associations of the Inflammatory Marker YKL-40 with Measures of Obesity and Dyslipidaemia in Individuals at High Risk of Type 2 Diabetes. PLoS One (2015) 0.75
Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival. PLoS One (2015) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Evolving concepts of rheumatoid arthritis. Nature (2003) 14.31
SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res (2005) 7.34
A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med (2007) 6.02
Rheumatoid arthritis. Lancet (2009) 4.69
Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med (2008) 4.58
Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol (2011) 3.25
Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull (2006) 2.69
Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics (1997) 1.91
YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol (2008) 1.78
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol (2000) 1.74
The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J (2004) 1.64
Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res (1992) 1.60
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem (2011) 1.50
Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis (2007) 1.49
Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol (2009) 1.46
Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum (1997) 1.46
Chondrex: new marker of joint disease. Clin Chem (1998) 1.43
Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem (2005) 1.42
DANBIO--powerful research database and electronic patient record. Rheumatology (Oxford) (2011) 1.40
Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem (2003) 1.39
Plasma YKL-40: a potential new cancer biomarker? Future Oncol (2009) 1.37
Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet (2006) 1.37
A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther (2011) 1.34
The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol (2009) 1.27
Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. Curr Opin Rheumatol (2009) 1.27
A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med (2007) 1.22
Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med (2008) 1.19
Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes (2008) 1.14
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum (1999) 1.11
IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine (2011) 1.09
A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol (2008) 1.05
Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol (2008) 1.05
High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol (2007) 1.01
Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol (2010) 1.01
Genetic epidemiology of rheumatoid arthritis. Curr Opin Rheumatol (2006) 0.97
Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis (2002) 0.97
Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One (2009) 0.96
Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells. J Immunol (2001) 0.90
Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem (2010) 0.90
Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol (2002) 0.88
Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology (Oxford) (2000) 0.87
Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a potential functional mechanism. Biol Psychiatry (2008) 0.86
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol (2003) 0.83
The chitinase 3-like 1 gene and schizophrenia: evidence from a multi-center case-control study and meta-analysis. Schizophr Res (2010) 0.81
Is the sugar always sweet in intestinal inflammation? Immunol Res (2007) 0.81
Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits. PLoS One (2009) 0.79
Lack of evidence for association of two functional SNPs of CHI3L1 gene (HC-gp39) with rheumatoid arthritis. Rheumatol Int (2010) 0.79
The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol (2000) 0.78
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology (2007) 2.95
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med (2009) 2.10
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma (2011) 1.69
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica (2006) 1.68
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 1.61
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood (2004) 1.57
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica (2012) 1.45
Additional molecular bases of the clinically important p blood group phenotype. Transfusion (2003) 1.43
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol (2012) 1.43
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res (2003) 1.42
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma (2012) 1.42
Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res (2011) 1.41
YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol (2002) 1.29
MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol (2009) 1.26
CtIP Mutations Cause Seckel and Jawad Syndromes. PLoS Genet (2011) 1.26
Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis (2010) 1.25
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 1.24
Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer (2005) 1.22
Genome-wide scans using archived neonatal dried blood spot samples. BMC Genomics (2009) 1.20
Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol (2003) 1.18
High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer (2002) 1.18
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers (2008) 1.18
The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1. PLoS One (2011) 1.17
Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion (2011) 1.16
Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology (2009) 1.16
Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes (2008) 1.14
Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg (2012) 1.14
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol (2006) 1.11
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes (2005) 1.10
Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci (2005) 1.10
Multifactorial etiology of recurrent miscarriage and its scientific and clinical implications. Gynecol Obstet Invest (2008) 1.10
IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine (2011) 1.09
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep (2003) 1.09
Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis (2008) 1.08
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother (2008) 1.07
The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford) (2013) 1.07
Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta (2011) 1.07
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother (2007) 1.05
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res (2005) 1.04
Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica (2010) 1.04
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica (2003) 1.03
Association of HY-restricting HLA class II alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a firstborn boy. Hum Mol Genet (2009) 1.02
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother (2004) 1.02
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res (2012) 1.02
Low serum level of mannan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion. Am J Obstet Gynecol (2002) 1.01
Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol (2010) 1.01
Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis (2002) 1.00
Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics (2012) 1.00
Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer (2010) 0.99
Expression of HOXA genes in patients with multiple myeloma. Leuk Lymphoma (2004) 0.98
Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue. Am J Clin Pathol (2011) 0.98
YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer (2009) 0.97
Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res (2008) 0.97
Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. J Biol Chem (2003) 0.97
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas (2012) 0.97
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. J Rheumatol (2008) 0.97
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat (2007) 0.96
A genome-wide study of panic disorder suggests the amiloride-sensitive cation channel 1 as a candidate gene. Eur J Hum Genet (2011) 0.95
Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst (2005) 0.94
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand (2003) 0.93
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy (2010) 0.93
Storage time of allogeneic red blood cells is associated with risk of severe postoperative infection after coronary artery bypass grafting. Eur J Cardiothorac Surg (2010) 0.93
YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol (2007) 0.93
Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/PPP1R13L/iASPP. BMC Med Genet (2008) 0.92
SorLA regulates the activity of lipoprotein lipase by intracellular trafficking. J Cell Sci (2011) 0.92
An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) (2009) 0.92
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma (2010) 0.91
Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica (2008) 0.91
Mannan-binding lectin and procalcitonin measurement for prediction of postoperative infection. Crit Care (2005) 0.91
YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol (2009) 0.91
Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol (2005) 0.91
Polymorphisms in mannan-binding lectin (MBL)-associated serine protease 2 affect stability, binding to MBL, and enzymatic activity. J Immunol (2009) 0.90
Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines. PLoS One (2011) 0.90
Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development. Am J Physiol Heart Circ Physiol (2010) 0.90
YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem (2011) 0.90
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol (2011) 0.90
Fruit and vegetable consumption and lymphoma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control (2007) 0.90